Melbourne-based biotech manufacturer CSL says it is looking at how it can help fight the deadly Ebola virus.
According to AAP, the blood plasma product and vaccine maker is talking with the World Health Organisation (WHO) about the possibly of it helping collect antibodies from the blood of survivors of the virus.
According to CSL chairman Professor John Shine, the company is not directly part of any effort to develop a vaccine.
"But in the meantime we are in dialogue and discussion and interaction with the World Health Organisation because it has become apparent that those patients who do recover from Ebola have antibodies in their blood against the virus," he told shareholders at its annual general meeting on Wednesday.
"So it should be theoretically possible to purify those antibodies and use that as therapy to treat patients that are infected."
As the ABC reports, the current outbreak of the Ebola virus was first reported in West Africa in March. 4,447 people have been killed by the current outbreak.
According to the WHO, the number of new people infected could climb to 10,000 a week by the end of the year.